Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is a biopharmaceutical leader focused on rare neuromuscular and neurological disorders, including its FDA-approved therapy for Lambert-Eaton Myasthenic Syndrome (LEMS). This page provides official updates and analysis of Catalyst's developments in drug commercialization, regulatory milestones, and clinical research.
Investors and healthcare professionals can monitor critical updates including FDA decisions, clinical trial progress, and strategic partnerships. All content is sourced from verified filings, press releases, and reputable financial analysis to ensure accuracy.
Key focus areas include developments around Firdapse® commercialization, pipeline advancements for CPP-115, and regulatory strategies for orphan drug designations. The curated news collection enables efficient tracking of Catalyst's position in the competitive rare disease therapeutics market.
Bookmark this page for consolidated access to Catalyst's latest business and scientific developments. Check regularly for updates impacting the company's growth trajectory in a sector where regulatory approvals directly influence market performance.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced that President and CEO Rich Daly and other management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:45pm PST. The presentation will be webcast from the company’s investor website and a replay will be available for at least 30 days.
The company described itself as a commercial-stage biopharmaceutical focused on in-licensing, developing, and commercializing therapies for rare and difficult-to-treat diseases.
Catalyst Pharmaceuticals (Nasdaq: CPRX) said President and CEO Rich Daly and other executives will participate in the Bank of America CNS Therapeutics Virtual Conference on Monday, December 8, 2025 at 12:35pm ET.
The session will be available via webcast on the company investor website at www.catalystpharma.com, and a replay will be accessible for at least 30 days after the presentation.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced on November 19, 2025 that it ranked #304 on the 2025 Deloitte Technology Fast 500™. The ranking is based on percentage revenue growth from fiscal year 2021 to 2024, during which Catalyst reported 249% revenue growth. The company attributes the growth to portfolio momentum and commercial execution and noted this is the second consecutive year it earned a Fast 500 placement, improving from #452 in 2024. The announcement frames the recognition as evidence of sustained commercial progress and operational discipline while reaffirming commitment to patients and long-term growth.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced that President & CEO Rich Daly and other management will participate in Citi’s 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 2025.
The company’s presentation is scheduled for 1:00 PM ET. A live webcast will be available via the Investors section at www.catalystpharma.com, and a replay will be available for at least 30 days after the presentation.
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 2025 total revenues of $148.4M, driven by FIRDAPSE, AGAMREE and FYCOMPA, and raised full‑year 2025 total revenue guidance to $565M–$585M.
Key metrics: FIRDAPSE Q3 net revenue $92.2M (+16.2% YoY), AGAMREE Q3 net revenue $32.4M (+115.2% YoY), FYCOMPA Q3 net revenue $23.8M (‑25.8% YoY). GAAP net income was $52.8M and non‑GAAP net income was $86.1M for the quarter. Cash and cash equivalents were $689.9M as of September 30, 2025.
The company announced a $200M share repurchase program (Oct 1, 2025–Dec 31, 2026) and noted a pending patent trial with a tentative date in March 2026.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced on November 4, 2025 that it was named to the BioSpace 2026 Best Places to Work list for the second consecutive year, ranking 13 among 30 U.S. small employers.
The recognition reflects BioSpace's evaluation of workplace culture, career growth, leadership and innovation, based on votes and ratings from thousands of life‑science community members. Catalyst highlighted its mission to develop therapies for rare diseases and credited its team for the award. This is BioSpace's fifth Best Places to Work list.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025. Rich Daly, President and CEO, and other members of management will present.
Presentation time: 2:00 pm GMT. A live webcast will be available in the Investors section at www.catalystpharma.com, and a replay will be available for at least 30 days.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release its third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a conference call and live webcast on Thursday, November 6, 2025 at 8:30 AM ET to discuss results and provide a business update.
Investors can join by phone (US/Canada: 877-407-8912; International: 201-689-8059) or via the webcast in the Investors section at www.catalystpharma.com. A replay of the webcast will be available on the company website for at least 30 days following the event.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced multiple scientific poster presentations and sessions for October 2025 reporting real-world and clinical analyses. Presentations include Duchenne muscular dystrophy analyses on glucocorticoid duration, respiratory decline, and adverse outcomes, plus a poster on amifampridine phosphate dosing in Lambert Eaton myasthenic syndrome.
Conferences and dates: Child Neurology Society posters on Oct 9, 2025; AANEM poster sessions on Oct 30–31, 2025; and MGFA scientific poster on Oct 29, 2025. Presenters named include Steven D Woods, Bridget McGowan, Yaacov Anziska.
Catalyst Pharmaceuticals (NASDAQ:CPRX) announced a new $200 million share repurchase program effective from October 1, 2025, to December 31, 2026. The company plans to fund the buyback using its existing cash reserves.
As of June 30, 2025, Catalyst maintains a strong financial position with over $650 million in cash and cash equivalents and no funded debt. The repurchases may be executed through open market or privately negotiated purchases, with timing and volume depending on various market factors. The company maintains flexibility to suspend or terminate the program at any time.
FAQ
What is the current stock price of Catalyst Pharmaceuticals (CPRX)?
What is the market cap of Catalyst Pharmaceuticals (CPRX)?
